Loading clinical trials...
Loading clinical trials...
A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).
Conditions
Interventions
Chemotherapy
Cross-over to Osimertinib
Locations
150
United States
Research Site
Anaheim, California, United States
Research Site
Orange, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Norwalk, Connecticut, United States
Research Site
Gainesville, Florida, United States
Research Site
Orlando, Florida, United States
Start Date
August 4, 2014
Primary Completion Date
April 15, 2016
Completion Date
December 15, 2023
Last Updated
January 7, 2025
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions